AI Content House
Unleash the Power of Generative AI for Drug Discovery and Launch.
With H1’s generative AI, global life sciences organizations can accelerate clinical research and ultimately pave the way for groundbreaking innovations in the field. Embedded in H1’s flagship products, GenosAI™ can simplify complex queries, access insights from vast amounts of unique data sources, and accelerate time to market.
Introducing H1’s GenosAI™
Users of H1’s clinical trial intelligence platform, Trial Landscape, can now supercharge their trial design, diversity planning, and PI & Site selection with insights from GenosAI™. GenosAI™ is a generative AI tool that uses Natural Language Processing (NLP) technology to analyze and respond to all types of data and intelligence questions. Not only can clinical and feasibility teams quickly unlock the power of H1’s global data platform but they can also break down data silos within their internal ecosystem by overlaying GenosAI™ on internal data sources to create a holistic source of truth for their discovery to launch initiatives.
Here are 3 ways GenosAI™ can help you:
Site Selection & Feasibility
- What sites have run diabetes phase 2 clinical trials in the past 2 years?
- Which of these trials had BRCA 1/2 positive as inclusion criteria?
Competitive Intelligence & Trial Design
- What are all the trials running in breast cancer phase 3?
- What is the breakdown of breast cancer phase 3 trials by country?
- What are the breast cancer phase 3 trials running in Spain currently?
Diversity and Inclusion
- Which doctors have been administering next-generation sequencing testing for African American patients?
- Of these doctors, which have been principal investigators of phase 3 trials?
Meet GenosAI™
Speak with our team to explore the many ways GenosAI™ can help you accelerate discovery and launch.
AI Content and Resources
H1 Boosts Flagship Clinical Trial Intelligence Platform with Generative AI to Accelerate Clinical Trials
Can AI Transform The Way Pharma Engages Thought Leaders?
In this episode Ariel Katz, Co-Founder & CEO at H1 joins to discuss how AI can transform the way Pharma engages thought leaders.
Scaling Smart Solutions with AI in Health: Unlocking Impact on High potential use cases
The healthcare sector is grappling with critical challenges, such as a shortage of frontline workers, health disparities and escalating spending. Artificial intelligence (AI) promises transformative potential to tackle these issues.
AI for Hire: 5 Considerations for AI Innovation Workforce Strategies
By now, pretty much everybody agrees that artificial intelligence (AI) will change all of our lives forever. From transportation to quality control, from education to medicine, few if any area of our lives will remain unaltered.
H1 Brings AI to Trial Landscape
Read featured report
By utilizing conversational AI, the process of conducting clinical trials can be made more effective and patient-focused. This technology has the power to boost data gathering and evaluation, leading to cost savings while accelerating medical breakthroughs with innovative medicines and cures. Read our latest Perspectives paper to hear how conversational AI can help you advance your clinical trials.
Explore Additional Resources
Modern KOL Connections: Engaging with Thought Leaders in the Age of AI
AI-powered attacks, AI potential and tailored cloud — healthcare tech predictions for 2024
Three Key Imperatives Needed To Advance AI’s Use In Clinical Trials
Ariel Katz, CEO & Co-Founder of H1 — Supporting Israel and Gaza, GenosAI, Trial Innovation, The Impact of AI in Healthcare, The Role of Data in Modern Medicine and Startup Advice
The Technology Conundrum
How AI Can Save Medical Affairs from Drowning in Data
Connect With Us At One of Our Upcoming Conferences.
Precision Clinical Trials Summit (San Diego)
Adam Wykoff presents “Navigating Clinical Trial Success: Unraveling the Complexities of Site and Investigator Selection with AI”
October 16-17th